The Clinical Lead (Executive Director, Senior Director or Director) is a clinical development leader accountable for advancing Ailux’s immunology pipeline from first-in-human through Ph1b proof-of-medicine (PoM) and proof-of-concept (PoC) trials, with scope to continue into later-stage development.
Acting as Clinical Lead and, where appropriate, Study-Responsible Physician, this leader will integrate clinical, translational, biomarker, disease-biology, and pathway strategies across IND/CTA-enabling development, FIH Phase 1, Phase 1b PoM, and Phase 2a PoC studies, with scope to continue into later-stage development.
The role provides end-to-end program and study leadership—from translational planning and protocol design through execution, medical monitoring, data analysis, interpretation, and communication of results.
In close partnership with Clinical Scientists, the Clinical Lead will coordinate cross-functional teams, translate therapeutic-area, disease, pathway, Target Product Profile, and value-creation strategies into executable plans, and deliver governance-approved milestones within timeline and budget commitments.
The Clinical Lead will connect Discovery Research, Translational Science, Biomarkers, and later-stage Clinical Development while partnering closely with Clinical Operations, Clinical Pharmacology, Regulatory, CMC, Safety, DMPK, Biomarkers, Project Management, Finance, and Business Development. The role also requires strong collaboration with Clinical Scientists, investigators, academic translational centers, external experts, contract research organizations (CROs), and development partners.
Reporting to the VP Clinical Lead, this individual will support program representation at governance meetings and external forums.
Ailux is an innovative biotechnology company focused on discovering and developing next-generation biologic therapeutics for immunological diseases with high unmet medical need. The company integrates advanced computational approaches with rigorous experimental, translational, and clinical science across the drug discovery and development continuum, enabling faster and more informed decision-making from target identification through clinical development.
As an AI-native biotech and wholly owned subsidiary of XtalPi, Ailux combines proprietary computational models with state-of-the-art wet lab capabilities to design differentiated therapeutics against challenging biological targets. The company has established strategic partnerships with leading pharmaceutical organizations, providing external validation of its scientific platform and discovery capabilities.
Ailux’s vision is to build a fully integrated, end-to-end drug discovery and development organization capable of delivering the next generation of medicines for patients with chronic immunological diseases.
Backed by an experienced leadership team, leading scientific advisors, and a highly multidisciplinary organization, Ailux is approaching a key inflection point as its first wave of therapeutic programs advances toward clinical development. This is an opportunity to play a central role in leading programs from pre-clinical development into the clinic and through clinical proof-of-concept, shaping the pipeline and development culture of a rapidly growing biotechnology company.